Pharmacology 7250-209-205, 301 Henrietta Street, Pharmacia Corporation, Kalamazoo, MI 49001, USA
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
The mechanism of action is inhibition of the initiation phase of translation by blocking formation of the 70S subunit initiation complex.3 This mechanism of action is distinctive of the oxazolidinones, and consequently no inherent cross-resistance has been found in bacterial strains resistant to other protein synthesis inhibitors or other antimicrobial agents, including multidrug-resistant strains.1,2
A rabbit model of aortic valve endocarditis developed by Garrison & Freedman4 continues to be the predominant tool to define the experimental effects of antibiotic agents for treatment of this disease. Bacterial endocarditis is a lethal infection that requires the administration of high levels of bactericidal antibiotics for prolonged periods of time for cure. A significant percentage of patients with endocarditis fail therapy or suffer relapse, either because resistance develops or because not all of the infection is cleared.5
The efficacy of linezolid in treating serious S. aureus infections such as endocarditis has not been determined. To address this issue, we compared the therapeutic activities of a range of oral linezolid doses from 25 to 75 mg/kg tds, and a standard 25 mg/kg iv bd vancomycin dose in a rabbit model of aortic valve endocarditis.
![]() |
Materials and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
All procedures in this study were in compliance with the Animal Welfare Act Regulations (9 CFR parts 1, 2 and 3) and with the Guide for the Care and Use of Laboratory Animals (ILAR 1996).
Experiments were performed on male, specific pathogen-free (SPF) New Zealand White rabbits weighing 2.02.5 kg. Employing sterile surgical technique under intramuscular ketamine (35 mg/kg) and xylazine (5 mg/kg) anaesthesia, a polyethylene catheter (PE-50) was inserted into the right carotid artery and advanced across the aortic valve into the left ventricle. The catheter was sutured in place for the duration of the study. Only data from animals with correct catheter placement upon autopsy were included. Rabbits were infected 24 h after surgery with 3.5 x 106 cfu of S. aureus UC-9258. Forty-eight hours after infection, control rabbits were killed, and linezolid or vancomycin treatment was initiated. Rabbits were killed 8 h after the final dose of linezolid or 12 h after the final dose of vancomycin. Aortic valve vegetations, blood and ventricular myocardium were removed and homogenized, and quantitative bacterial counts were determined by serial dilution and expressed as log10 cfu/g of tissue. Culture-negative samples were assigned a value equal to the lowest level of detection based on tissue weight and one colony in an undiluted sample.
Antimicrobial agents and treatment groups
Linezolid was prepared as a 25 mg/mL oral suspension in Sterile Vehicle 122 (Pharmacia Corporation, Kalamazoo, MI, USA). Vancomycin (Sigma Chemical Co., St Louis, MO, USA) was dissolved in sterile saline at 25 mg/mL, and was administered intravenously via a marginal ear vein. Rabbits were assigned randomly to the following treatment groups: control (n = 14); vancomycin 25 mg/kg bd for 5 days (n = 11); linezolid 75 mg/kg tds for 5 days (n = 10); linezolid 50 mg/kg tds for 5 days (n = 12); and linezolid 25 mg/kg tds for 5 days (n = 5). Two rabbits were excluded due to improper catheter placement. One rabbit receiving the 25 mg/kg dose of linezolid was killed early owing to illness and was therefore excluded from analysis.
Bacterial strain
A clinical isolate of S. aureus (UC-9258) from an endocarditis patient was used to produce infection in these studies. The MIC for the isolate was 2 mg/L for linezolid, <0.5 mg/L for vancomycin and 2 mg/L for methicillin [methicillin-susceptible S. aureus (MSSA)]. The mean bactericidal concentration (MBC) of linezolid was >64 mg/L for this strain.
UC-9258 was diluted in sterile saline and administered as a 1 mL intravenous bolus of 3.5 x 106 cfu through a marginal ear vein.
Plasma analysis
Blood samples were obtained at 1 and 8 h after the initial linezolid dose, at 1 h after the penultimate linezolid dose and upon killing. Plasma was frozen until assayed for linezolid levels.
The plasma samples were analysed by high performance liquid chomatography/mass spectrometry/mass spectrometry (HPLC/MS/MS) using a PE SCIEX API 3000 triple quadruple mass spectrometer with a heated nebulizer ion source and a Hewlett Packard 1100 HPLC as the solvent delivery/injection system. The HPLC and mass spectrometer were controlled by PE SCIEX API MassChrom software version 1.1. HPLC mobile phase solutions used were 43% methanol with 2 mM ammonium acetate and 57% H2O with 2 mM ammonium acetate.
Statistical analysis
The results are reported as mean ± s.d. Comparisons of bacterial densities in blood, ventricular myocardium and aortic valve vegetation used the KruskalWallis one-way analysis of variance on ranks followed by Dunn's test for multiple comparisons. A P value 0.05 was considered statistically significant.
![]() |
Results and discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
In conclusion, this study shows that, like vancomycin, linezolid is effective for the treatment of experimental staphylococcal endocarditis in rabbits when plasma drug levels remain above the MIC, as has been demonstrated with other agents in this model.7 This study demonstrates the first evidence of the effectiveness of linezolid for the treatment of deep-seated experimental infections such as endocarditis.
![]() |
Acknowledgments |
---|
![]() |
Notes |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
2 . Ford, C. W., Hamel, J. C., Wilson, D. M., Moerman, J. K., Stapert, D., Yancey, R. J. et al. (1996). In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Antimicrobial Agents and Chemotherapy 40, 150813.[Abstract]
3 . Shinabarger, D. L., Marotti, K. R., Murray, R. W., Lin, A. H., Melchior, E. P., Swaney, S. M. et al. (1997). Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrobial Agents and Chemotherapy 41, 21326.[Abstract]
4 . Garrison, P. K. & Freedman, L. R. (1970). Experimental endocarditis. 1. Staphylococcal endocarditis in rabbits resulting from placement of a polyethylene catheter in the right side of the heart. Yale Journal of Biology and Medicine 42, 394410.[ISI][Medline]
5 . Durack, D. T. & Beeson, P. B. (1972). Experimental bacterial endocarditis. 1. Colonization of a sterile vegetation. British Journal of Experimental Pathology 53, 449.[ISI][Medline]
6 . Chambers, H. F. & Sande, M. A. (1984). Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 26, 614.[ISI][Medline]
7 . Carbon, C. (1990). Impact of the antibiotic dosage schedule on efficacy in experimental endocarditis. Scandinavian Journal of Infectious Disease 74, Suppl., 16372.
8 . Stalker, D. J., Wajszczuk, C. P. & Batts, D. H. (1997). Linezolid safety, tolerance and pharmacokinetics following oral dosing twice daily for 14.5 days. In Program and Abstracts of the Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 1997. Abstract A-115, p. 23. American Society for Microbiology, Washington, DC.
9 . Zurenko, G. E., Yagi B. H., Schaadt, R. D., Allison, J. W., Kilburn, J. O., Glickman, S. E. et al. (1996). In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrobial Agents and Chemotherapy 40, 83945.[Abstract]
Received 26 June 2000; returned 21 September 2000; revised 31 October 2000; accepted 20 November 2000